Investigation and targeting of alternate binding site in ERR?
Ended Project Grant Awarded Last action
- Award ID
- R21DK132605
- Recipient
-
University Of Health Sciences And Pharmacy In ST. Louis UEI NMMKG6CCEMW4
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,349,460
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Funding
-
- $1,155,572.00 Federal
- $193,888.00 Non-federal
- Place of performance
- Missouri, USA
Award details come from USAspending.gov.
Description
- Abstract
- The world health organization announced a marked increase in patients with diabetes; from 108 million in 1980 to 422 million in 2014. Diabetes causes severe complications including blindness, heart attacks and lower limb amputation with an estimated 1.5 million deaths annually caused by diabetes. Therefore, there is growing interest in identifying novel drug targets and alternative therapeutics approaches. Estrogen-related receptor a (ERRA) is a nuclear hormone receptor that regulate gene expressions related to anti-inflammatory activities, oxidative phosphorylation, biogenesis and fatty acid metabolism. Large body of data suggest ERRA as a promising therapeutic target in treating metabolic disorders, such as type 2 diabetes and metabolic syndrome. The identification of ERRA selective small molecule agonists would be valuable chemical probes and pharmacological tools to further explore the role of ERRA in diabetes. However, existing ERRA agonists lack in vivo potency and selectivity that are required for their use as chemical probes. In addition, there are no X-RAY crystal structures available for ERRA bound agonists, which hindered the discovery of specific ERRA agonists. Understanding the molecular basis of agonist ligand binding to ERRA is crucial for identification and optimization of novel potent and specific agonists. Initial preliminary studies using molecular dynamics simulations, revealed the presence of novel alternate binding site in ERRA. Targeting this alternate site holds premise for discovery of novel ERRA agonists. We propose two specific aims to be done in two phases: 1) investigation of the mechanism of agonist ligand binding to ERRA orthosteric and allosteric sites using a combination of computational and experimental approaches. This step is essential to characterize low energy state structural ensembles favouring agonist binding to ERRA. 2) implementation of computer-based drug design approaches such as structure-based virtual screening for discovery of new molecular scaffolds that bind and selectively activate ERRA. These aims will provide novel, first in class ligands that selectively activate ERRA and can be used as chemical probes for investigation of their role in diabetes in future grant proposals.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $186,132 | $0 | |
| Amendment | $193,888 | $0 | |
| Amendment | $193,888 | $0 | |
| Amendment | $193,888 | $0 | |
| Amendment | $193,888 | $193,888 | |
| Original award | $193,888 | $0 |
Quick answers
Who received award R21DK132605?
R21DK132605 was awarded to University Of Health Sciences And Pharmacy In ST. Louis by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on April 1, 2022.
How much is award R21DK132605 worth?
$1,349,460 has been obligated on R21DK132605: $1,155,572 in federal funding and $193,888 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award